Managing the patient presenting with xerostomia: a review.
OBJECTIVE
Patients complaining of a dry mouth can present themselves to various clinicians such as the primary care physician, dentists, otolaryngologists and/or oral surgeons. The aim of our review is to provide a systematic method of assessing and managing these patients based on current best evidence published in the literature.


METHODS
A literature search was performed on 20th April 2009 using MEDLINE and EMBASE using the terms dry mouth and xerostomia in combination with diagnosis, management, investigations and treatment.


RESULTS
There appears to be little correlation between patient symptoms and objectives tests of salivary flow. Therefore clinical management should be based on patient symptoms. There is good evidence to support that xerostomia is commonly associated with anticholinergic drugs, and altering such agents plays an important role in the management of these patients. In patients with residual salivary gland function, the use of salivary stimulants appears to be more beneficial than salivary substitutes.


CONCLUSIONS
Xerostomia can be debilitating and primarily affects the middle aged and elderly population. The most common causes of xerostomia include medications with anticholinergic properties, dehydration, diabetes and radiotherapy for head and neck cancer. Treatment of xerostomia essentially involves addressing the cause followed by salivary substitutes and/or salivary stimulants.
Visvanathan
V
V
Department of ENT/Head and Neck Surgery, Leeds General Infirmary, Leeds, UK.
Nix
P
P
D015670:Acupuncture Therapy; D001205:Ascorbic Acid / Q000627:therapeutic use; D002638:Chewing Gum; D006801:Humans; D008293:Malates / Q000627:therapeutic use; D008487:Medical History Taking; D018721:Muscarinic Agonists / Q000627:therapeutic use; D010277:Parasympathomimetics / Q000627:therapeutic use; D010808:Physical Examination; D010862:Pilocarpine / Q000627:therapeutic use; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D012017:Referral and Consultation; D012464:Saliva, Artificial / Q000627:therapeutic use; D014987:Xerostomia / Q000209:etiology / Q000628:therapy*
D002638:Chewing Gum; D008293:Malates; D018721:Muscarinic Agonists; D010277:Parasympathomimetics; D011837:Radiation-Protective Agents; D012464:Saliva, Artificial; D010862:Pilocarpine; C030298:malic acid; D001205:Ascorbic Acid